NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares BOCA RATON, Fla. and JERUSALEM, Dec. 01, 2020 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on its stem cell-based technology platform,...

NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance; Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments Screening of resistance diagnostics completed for twelve standard-of-care cancer treatments representing a significant portion of cancer treatment protocols. COVID-19 research collaboration initiated...

NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic BOCA RATON, Fla. and JERUSALEM, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on stem-cell-based diagnostic technology to...

Hollywood Media Changes Name and Stock Symbol to NovelStem International Corp. and “NSTM” to Reflect Focus on Stem Cell-Based Diagnostics to Better Select Cancer Chemotherapies BOCA RATON, Fla. and JERUSALEM, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Hollywood Media Corp. (OTC Pink: HOLL) announced today it has changed its corporate name to NovelStem International Corp....

Hollywood Media Completes Transformational Investment in NewStem, Israel-Based Developer of Haploid Stem Cell-Based Diagnostics to Predict Chemotherapy Resistance Raises $1.925 Million to Support a $2 Million Initial Investment in NewStem Ltd.Appoints New Board of Directors Led by Jan Loeb as ChairmanForms New Leadership Team with Deep Healthcare ExpertisePlans...